Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
(OP:
SDZNY
)
44.18
-0.38 (-0.85%)
Streaming Delayed Price
Updated: 3:51 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about SDZNY
3 Spinoff Stocks You Should Buy Now: July 2024
July 15, 2024
Spinoff stocks often take time to gain their footing in the market giving investors an opportunity to get in early.
Via
InvestorPlace
Upcoming Stock Spinoffs: Should You Pounce or Pass?
July 04, 2024
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in.
Via
InvestorPlace
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
April 30, 2024
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost.
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Generic/Biosimilar Player Sandoz Settles US Price Fixing Case For $265M
February 29, 2024
Sandoz US, settles Generic Pharmaceuticals Pricing Antitrust Litigation for $265 million, addressing claims from direct purchasers without admitting wrongdoing. Post-approval, litigation continues with...
Via
Benzinga
Why Is Cancer Immunotherapy Focused-Coherus BioSciences Stock Trading Higher Today?
January 22, 2024
Coherus BioSciences agreed to sell its ophthalmology franchise for $170M to Sandoz. This aligns with CHRS' focus on oncology and will help reduce debt and overhead costs.
Via
Benzinga
Venue Turmoil: Pharma Companies Oppose States' Bid to Relocate Price-Fixing Cases
December 04, 2023
Major pharmaceutical firms, including generic manufacturers such as Teva Pharmaceutical Industries Limited (NYSE: TEVA), Sandoz Group (OTC:
Via
Benzinga
Novartis Q3: Earnings Beat, Raised Operating Profit Outlook & More
October 24, 2023
Novartis AG (NYSE: NVS) reported
Via
Benzinga
Topics
Earnings
Exposures
Financial
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.